Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Immunic AG. (2/1/17). "Press Release: Immunic Adds EUR 4 Million in Funding to Further Boost Development. Series A Financing Round Extended to EUR 21.7 Million". Planegg-Martinsried & Magdeburg.

Organisations Organisation Immunic AG
  Group Immunic (Group)
  Organisation 2 IBG Risikokapitalfonds II GmbH & Co. KG
  Group Saxony-Anhalt (govt region)
Products Product vidofludimus calcium (IMU-838, Immunic)
  Product 2 venture capital
Index term Index term Immunic–Saxony-Anhalt (govt): investment, 201702 investment Series A €4m by new investor IBG bringing total to €21.7m
Persons Person Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
  Person 2 Vlachou, Angelika (High-Tech Gründerfonds 202110 VC Professional formerly bmp 201702 Investment Manager bmp)

> Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement

> Expanded funding accelerates further development of IMU-838 and IMU-366 in chronic inflammatory and autoimmune diseases

Immunic AG (Immunic Therapeutics), a recently founded private biotech company in Martinsried near Munich, Germany, today announced that it has expanded its Series A round of financing now totaling EUR 21.7 million of preferred stock financing. New investor IBG Risikokapitalfonds II GmbH & Co. KG joined the international group of investors, led by LSP and co-lead LifeCare Partners.

Immunic was founded in April 2016 with the purpose to advance promising drug development projects to clinical proof-of-concept. The company currently develops two development programs IMU-838 and IMU-366 in the field of Th17 and Th1 mediated chronic inflammatory and autoimmune diseases like ulcerative colitis, Crohn’s disease and psoriasis.

Dr. Daniel Vitt, Immunic’s Chief Executive Officer, says: “We are very excited that IBG joins the group of renowned investors and adds another four million Euro of equity financing to Immunic’s series A. This step is very important to speed up development of our two key assets IMU-838 in the field of IBD and IMU-366 for treating autoimmune diseases with high unmet medical need.”

“We are convinced that Immunic’s unique therapeutic products managed by an experienced team will substantially advance the therapeutic options in the underserved field of chronic inflammatory diseases”, states Dr. Angelika Vlachou, Investment Manager at bmp. “We are delighted to be able to accompany this development with the IBG funds and help to build up a research branch office in Halle (Saale).”

– Press release ends –

Further Information

About Immunic AG

Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block Th17- and Th1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and ROR?t (IMU-366 program) relevant to diseases such as Ulcerative Colitis, Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.

Further information:

About the IBG funds

The IBG funds are based in Magdeburg and are the venture capital funds of the federal state of Sachsen-Anhalt. The IBG funds provide equity capital financing for young innovative technology companies with long-term and above-average growth potential that are headquartered in or have a branch office in Sachsen-Anhalt. The IBG funds have already invested in over 100 companies since 1996. Currently approximately 50 companies are part of the portfolio. The IBG funds are managed by bmp Beteiligungsmanagement AG, Berlin and Magdeburg.

Further information:

About bmp

With background of experience of more than 250 investments in almost all technology segments, the majority of which were early phase, bmp is one of the most experienced venture capital investors in Germany. In addition to direct investments, bmp´s activities also include managing risk capital funds for KfW Bankengruppe and DEG – Deutsche Investitions- und Entwicklungsgesellschaft. bmp currently manages the IBG funds in Sachsen-Anhalt and the Frühphasenfonds Brandenburg fund.

Further information:


Dr. Daniel Vitt, CEO
Immunic AG
Am Klopferspitz 19
82152 Planegg-Martinsried
T: +49 89 250079460

Dr. Angelika Vlachou
bmp Beteiligungsmanagement AG
Kantstraße 5
39104 Magdeburg
T + 49 391 5328140

Record changed: 2023-06-05


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Immunic (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top